Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2

Technology appraisal guidance
Reference number: TA257
Published: 27 June 2012

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Cameron

Dr David Cameron, Professor of Oncology nominated by NHS Quality Improvement Scotland

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Cameron

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Cameron
27 April 2012
(147.55 Kb 42 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 25 April 2012